New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
59.43
1.09
+1.87%
Follow BMY
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow of $9.3B covered $5.1B of dividends and buybacks. Cash fell by $6.2B. What is a cash flow statement?
- Free cash flow
- $9.3B 87.2% of operating cash flow
- Returned to shareholders
- $5.1B 55.4% of free cash flow
- Debt, net
- −$6.3B repaid
- Change in cash
- −$6.2B over the period
| Operating cash flow | 10.7 |
|---|---|
| Capital expenditures | −1.4 |
| Free cash flow | 9.3 |
| Acquisitions, net | −2.2 |
| Into investments, net | −1.8 |
| Dividends | −5.1 |
| Buybacks, net | 0.0 |
| Debt repaid, net | −6.3 |
| Other | −0.1 |
| Change in cash | −6.2 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $14.2B | $13.3B | $12.8B | $10.7B |
| Capex | −$1.3B | −$1.4B | −$1.3B | −$1.4B |
| Free cash flow | $12.8B | $11.9B | $11.4B | $9.3B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
7,055.00 | 7,271.00 | 9,274.00 | 9,241.00 |
Depreciation & Amortization |
4,011.00 | 3,593.00 | 3,176.00 | 2,791.00 | |
Non Cash Items (Other) |
3,545.00 | 3,844.00 | 2,389.00 | 3,539.00 | |
Accounts Receivable Change |
(295.00) | 1,377.00 | 678.00 | 428.00 | |
Change in inventories |
(184.00) | (1.00) | (41.00) | 182.00 | |
Change in payables and accrued liability |
(2.00) | 492.00 | 450.00 | 542.00 | |
Income tax paid |
(4.00) | 129.00 | 228.00 | (464.00) | |
Change in other assets and liabilities |
30.00 | (3,415.00) | (3,372.00) | (5,607.00) | |
Other operating activities |
— | 53.00 | — | — | |
Operating Cash Flow |
14,156.00 | 13,306.00 | 12,782.00 | 10,652.00 | |
Capital expenditures |
(1,311.00) | (1,398.00) | (1,342.00) | (1,366.00) | |
Net Aquisitions |
(2,873.00) | (2,791.00) | (2,658.00) | (2,184.00) | |
Short Term Investments Change (Net) |
(25.00) | (31.00) | (1,399.00) | (2,212.00) | |
Long-Term Investments Change (Net) |
77.00 | 456.00 | 494.00 | 455.00 | |
Investing cash flow |
(4,132.00) | (3,764.00) | (4,905.00) | (5,307.00) | |
Repayment/Issuance of Debt (Net) |
(5,175.00) | (5,722.00) | (6,487.00) | (6,264.00) | |
Equity Repurchase (Common, Net) |
— | (193.00) | (83.00) | (28.00) | |
Dividends Paid (Total) |
(5,045.00) | (5,070.00) | (5,095.00) | (5,119.00) | |
Other financial activities |
(41.00) | — | — | — | |
Financing cash flow |
(10,348.00) | (10,915.00) | (11,709.00) | (11,441.00) | |
Exchange Rate Adjustment |
195.00 | 81.00 | (57.00) | (56.00) | |
Change in Cash |
(129.00) | (1,292.00) | (3,889.00) | (6,152.00) | |
Beginning Cash |
10,347.00 | 10,218.00 | 10,218.00 | 10,218.00 | |
Ending Cash |
10,218.00 | 8,926.00 | 6,329.00 | 4,066.00 | |
Stock Based Compensation |
553.00 | 555.00 | 553.00 | 552.00 | |
Dividends Paid (Common) |
(5,045.00) | (5,070.00) | (5,095.00) | (5,119.00) | |
Assets Liabilities Change (Total) |
(455.00) | (1,418.00) | (2,057.00) | (4,919.00) | |
Investments Change (Net) |
52.00 | 425.00 | (905.00) | (1,757.00) | |
Issuance/Purchase of Shares |
— | (193.00) | (83.00) | (28.00) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026